Přehled o publikaci
2023
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
EDELMANN, Jennifer, Jitka MALČÍKOVÁ and John C RICHESBasic information
Original name
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
Authors
EDELMANN, Jennifer, Jitka MALČÍKOVÁ and John C RICHES
Edition
Frontiers in Oncology, Lausanne, Frontiers Media S.A. 2023, 2234-943X
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
Switzerland
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
000937129200001
EID Scopus
2-s2.0-85148591746
Keywords in English
chronic lymphocytic leukemia (CLL); high-risk; TP53; definition; BTK - Bruton's tyrosine kinase; BCL2 (B-cell lymphoma 2); COVID-19; risk factor
Links
LX22NPO5102, research and development project.
Changed: 15/3/2024 03:48, RNDr. Daniel Jakubík
Abstract
V originále
The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions.
